E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group - Concepedia

Concepedia

Publication | Open Access

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

DOI Full Paper Access

112

Citations

19

References

2021

Year

Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. Onitilo,

Journal of Clinical Oncology

Abstract

The combination of exemestane and entinostat did not improve survival in AI-resistant advanced HR-positive, HER2-negative breast cancer.

References

	Year	Citations

Page 1